ENO1 and cholangiocarcinoma: Patients with high concurrent expression of all three proteins had significantly shorter overall survival and disease-free survival, indicating that the USP21–HSP90–HIF1A/ENO1 axis is not only involved in metabolic reprogramming but also holds potential prognostic value, offering new molecular markers and intervention targets for the metabolic targeted therapy of cholangiocarcinoma.